Plant-Made Proteins Market Outlook 2026–2038: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for Molecular Farming of Dairy, Egg and Meat Proteins in Soybean, Potato and Corn, Plant-Made Growth Factors and Biopharmaceuticals, and the Regulatory Path to Market — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how molecular farming — engineering crops such as soybean, potato, corn, pea and tobacco to produce animal and other high-value proteins in the field, then extracting them as ingredients — will give food, feed and pharmaceutical industries a protein source that scales with agriculture rather than with fermentation tanks, over the next twelve years. The field is small and close to its first products. Mozza Foods grows soybeans producing casein micelles at 4 grams per 100 grams of beans, targets 7 grams by the end of 2026, plans an FDA GRAS submission in mid-2027 and a late-2028 launch to dairy manufacturers and quick-service restaurants; Alpine Bio has harvested its first large-scale crop of casein soybeans under USDA permits and holds ten U.S. patents; Moolec Science's Piggy Sooy soybeans express pork protein at up to 26.6% of total protein and cleared USDA regulatory status review along with its bovine myoglobin pea, before Moolec merged with Bioceres Group in 2025; PoLoPo grows ovalbumin in potatoes; IngredientWerks expresses bovine myoglobin in corn; and BioBetter makes cultivated-meat growth factors in tobacco. The Good Food Institute counts 17 companies focused on molecular farming for alternative protein, with USD 196 million raised privately since 2017 and USD 14.4 million in 2024. No plant-made protein ingredient has yet been approved for food sale by a national regulator, and the U.S. pathway is being rewritten after a federal court vacated the USDA rule that created regulatory status review. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2038.

It is a focused 98-page decision brief for food and dairy manufacturers, ingredient companies, seed and agricultural biotechnology companies, cultivated-meat and biopharmaceutical producers, growers and processors, regulators and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which plant-made proteins reach market first, how regulation, extraction cost and identity preservation change the pace, and who captures the resulting value.

Molecular farming turns a crop into a bioreactor. A gene for the target protein — bovine casein, egg ovalbumin, porcine or bovine muscle proteins, a growth factor, a sweet protein — is inserted into a plant's genome, the plant expresses the protein in its seed, tuber or leaf, and the protein is extracted and purified after harvest. Soybeans suit casein because they already store large amounts of protein in the seed and are grown on about 90 million U.S. acres; potatoes suit egg proteins and offer starch and fibre as co-products; corn and pea carry myoglobin for meat analogues; tobacco grows fast and expresses growth factors and pharmaceuticals in leaf. Mozza's soybeans produce three of the four caseins assembled into micelles like those in milk, at 4 grams per 100 grams of beans with expression doubling each year; Alpine Bio protects casein from plant proteases and claims patents on any plant producing casein; Moolec's Piggy Sooy reaches 26.6% of total seed protein as porcine protein.

The economic case is scale. Precision fermentation makes the same proteins in tanks but is limited by fermenter capacity and sugar feedstock cost; a field of engineered soybeans scales with planted acres and existing crushing and extraction infrastructure, with soybean oil and soy protein as co-products, which is why Mozza says a USD 4 million extension of its Series A takes it to cost parity. Cultivated meat needs growth factors at a fraction of pharmaceutical prices, which tobacco-made production can offer. The pharmaceutical precedent exists — plant-made enzymes and vaccine antigens have been produced for years — and the food companies are engaged: Mozza reports relationships with most major dairy manufacturers in the United States and Europe.

The constraints are regulation, extraction, identity preservation and acceptance. Growing the crop needs USDA (or equivalent) clearance; selling the protein needs FDA GRAS or equivalent food approval, and no plant-made food protein has yet received one. The U.S. plant pathway itself is being rewritten after a federal court vacated the rule that created regulatory status review, with a 2026 USDA rulemaking on modified organisms under the Plant Protection Act under way. Extraction and purification must deliver food-grade protein at low cost; crops carrying animal proteins must be kept out of the commodity stream, which is why Mozza built its Grain Track identity-preservation system and PoLoPo has discussed closed-loop production with regulators; and consumers and non-GMO labelling bodies will decide how the products are received. The decade's question is which protein, crop and company clears the first food approval.

The plant-made proteins market — development spending, pilot ingredient and growth-factor sales, plant-made biopharmaceutical and enzyme production, and extraction and identity-preservation services in 2026, and ingredient sales thereafter — is estimated at USD 0.25–0.40 billion in 2026, led by plant-made biopharmaceuticals and enzymes, growth factors for cultivated meat, development programmes at molecular farming companies and pilot-scale casein, egg and meat protein production. Meticulous Next™ expects it to reach USD 5–8 billion by 2038, an indicative CAGR of 28–31%. Growth is driven by the first GRAS determinations and food approvals for casein and egg proteins around 2028 to 2030, by dairy and food manufacturer offtake at cost parity, by growth factors for cultivated meat, by expansion into meat proteins, sweeteners and enzymes and by identity-preserved acreage scaling through existing crushing and extraction infrastructure. The market starts small and development-weighted; the forecast depends on regulatory timing and extraction cost. The United States leads on crops, permits and the first filings; Israel and Europe contribute companies and growth-factor production; Latin America offers acreage through Bioceres; dairy, bakery, confectionery and cultivated-meat buyers lead demand.

The base case assumes first GRAS determinations for casein and egg proteins in 2028–2029, cost parity by 2030 and a workable U.S. plant pathway from 2027. An accelerated case assumes faster expression gains, early dairy offtake and a clear USDA rule, bringing the inflection to 2030 and lifting the 2038 value to the top of the range. A delayed case assumes regulatory uncertainty after the vacatur, extraction costs above parity or consumer resistance, pushing the inflection to 2034 and confining the market to growth factors, pharmaceuticals and enzymes.

Growth drivers

• Scale economics: engineered crops grow with planted acres and existing crushing and extraction infrastructure, with oil and protein co-products.
• Demand for animal-free dairy and egg proteins from dairy manufacturers, quick-service restaurants and food companies already engaged with Mozza and others.
• Cultivated-meat growth factors from tobacco at a fraction of pharmaceutical cost.
• Regulatory progress: USDA reviews completed for Moolec crops, permits for casein soybeans and GRAS submissions planned for 2027.

Enablers

• Plant genetic engineering and expression gains doubling casein yield annually.
• Soybean, potato and corn infrastructure for cultivation, crushing and extraction.
• Identity-preservation systems such as Grain Track and closed-loop production.
• Pharmaceutical precedent for plant-made enzymes and antigens.

Restraints and barriers

• No food approval yet for a plant-made protein ingredient; U.S. plant pathway under rewrite after the court vacatur.
• Extraction and purification cost to food grade.
• Identity preservation and allergen control for crops carrying animal proteins.
• Consumer acceptance and non-GMO labelling; thin funding of USD 14.4 million in 2024.

Five converging forces will determine how fast, and how far, molecular farming becomes a protein platform: (1) regulatory pathways for crops and ingredients; (2) expression and extraction economics to cost parity; (3) food and dairy manufacturer offtake; (4) cultivated-meat and pharmaceutical demand for plant-made inputs; and (5) identity preservation and consumer acceptance. The brief assesses each force for direction, speed and confidence.

The key players operating in plant-made proteins include Mozza Foods, Inc., Alpine Bio (formerly Nobell Foods), Moolec Science S.A. (Bioceres Group Limited), PoLoPo Ltd., Finally Foods, IngredientWerks, Inc., Miruku, NewMoo, Plantopia, Kinish, BioBetter Ltd., Bright Biotech Ltd., ORF Genetics ehf., Tiamat Sciences, Elo Life Systems, Inc., GreenLab, Inc., Ginkgo Bioworks Holdings, Inc., Shiru, Inc., iBio, Inc., Leaf Expression Systems Ltd, PlantForm Corporation, Medicago heritage platforms, Kentucky BioProcessing, Inc., Bayer AG (Bayer Crop Science), Corteva, Inc., Syngenta Group, BASF SE, Bioceres Crop Solutions Corp., Archer-Daniels-Midland Company, Bunge Global SA, Cargill, Incorporated, Ingredion Incorporated, Kerry Group plc, Fonterra Co-operative Group Limited, Danone S.A., Nestlé S.A., Bel Group, CSM Ingredients, Stray Dog Capital and the Good Food Institute. The brief profiles representative players in each archetype and assesses which are positioned to bring plant-made proteins to market.

The competitive landscape is forming around six archetypes. Molecular farming companies for food proteins. Plant-made growth-factor, enzyme and biopharmaceutical producers. Seed and agricultural biotechnology companies with crop platforms and acreage. Crushers, processors and extraction partners. Dairy, food and ingredient companies on the demand side. Investors, research institutes and industry bodies. Competitive intensity is low in 2026 and is expected to rise around the first food approvals through 2030.

Where value migrates.

In 2026 value sits in plant-made biopharmaceuticals and enzymes, growth factors for cultivated meat and development programmes for casein, egg and meat proteins. By 2032 it moves to approved casein and egg ingredients sold to dairy and food manufacturers at parity, identity-preserved acreage and extraction, growth factors as standard cultivated-meat inputs and licensing to seed and ingredient companies. By 2038 it settles in molecular farming companies with approved ingredients and patents, dairy and food manufacturers with secured supply, seed and agricultural biotechnology partners, and growers and processors with identity-preserved capacity. Precision fermentation retains proteins where tanks beat fields on purity and speed.

Capital is thin and focused: USD 14.4 million across the sector in 2024, USD 196 million privately since 2017, Mozza's USD 24 million with a USD 4 million extension to parity, Alpine Bio's USD 75 million 2021 Series B and PoLoPo's USD 2.3 million pre-seed, with Moolec folded into Bioceres and growth-factor producers earning revenue from cultivated-meat customers. Technical progress is measured in expression — casein doubling yearly toward 7 g/100 g, porcine protein at 26.6% of seed protein — and in field scale. Patent and research activity is concentrated in casein expression and micelle assembly, protease protection, seed and tuber storage of animal proteins, growth-factor production in leaf and extraction methods. The brief tracks four indicators: USDA clearances under the new framework, GRAS submissions and determinations, identity-preserved acreage and dairy manufacturer offtake agreements.

The United States leads on crops, permits, patents and the first filings through Mozza, Alpine Bio, IngredientWerks and Finally Foods; Israel contributes PoLoPo, BioBetter and others; Europe and New Zealand contribute Miruku, Plantopia and growth-factor producers; Latin America offers acreage through Bioceres. Dairy, bakery, confectionery and cultivated-meat buyers lead demand.